Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports.
Cardica, Inc. (NASDAQ: CRDC) shares spiked 21.30 percent to close at $1.31 a share Thursday. The stock traded between $1.28 and $1.61 on volume 4.77 million shares traded. The company announced that it has received 510(k) clearance of the MicroCutter XCHANGE 30 device. Shares of Cardica have fallen approximately 22.0 percent in the past year.
Get more information on Cardica and free access to the in-depth equity report at:
Endo Health Solutions Inc. (NASDAQ: ENDP) shares declined 1.30 percent to close at $69.02 a share Thursday. The stock traded between $68.01 and $70.29 on volume 1.46 million shares traded. The company announced that it has agreed to sell HealthTronics business to Altaris Capital Partners, LLC for up to $130.0 million. Shares of Endo Health Solutions have gained approximately 175.0 percent in the past year.
Get more information on Endo Health Solutions and free access to the in-depth equity report at:
Intercept Pharmaceuticals Inc. (NASDAQ: ICPT) shares soared 281.09 percent to close at $275.87 a share Thursday. The stock traded between $231.31 and $305.00 on volume of 6.81 million shares traded. The company announced that its FLINT trial of obeticholic acid (OCA) for the treatment of nonalcoholic steatohepatitis has met its primary endpoint and has been stopped early. Shares of Intercept Pharmaceuticals have gained approximately 700.0 percent in the past year.
Get more information on Intercept Pharmaceuticals and free access to the in-depth equity report at:
Sangamo Biosciences, Inc. (NASDAQ: SGMO) shares surged 38.32 percent to close at $18.88 a share Thursday. The stock traded between $15.70 and $19.12 on volume 10.37 million shares traded. The company and Biogen Idec have announced an exclusive worldwide collaboration and license agreement focused on the development of therapeutics for hemoglobinopathies. Shares of Sangamo Biosciences have gained approximately 180.0 percent in the past year.
Get more information on Sangamo Biosciences free access to the in-depth equity report at:
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.
Five Star Equities
Leave a comment...